Óɹú¼Ê·Î°©Ñо¿Ð»á(IASLC)Ö÷ÀíµÄ2023ÌìÏ·ΰ©´ó»á(WCLC)¼´½«ÓÚ9ÔÂ9ÈÕÖÁ12ÈÕÔÚÐÂ¼ÓÆÂ¾ÙÐС£¡£¡£¡£¡£±¾½ì´ó»á½«½ÒÏþº²ÉÖÆÒ©¼×»ÇËá°¢ÃÀÌæÄáÆ¬42ƪÁ¢ÒìЧ¹û£¬£¬£¬£¬£¬£¬£¬£¬ÌåÏÖÁ˹ú¼ÊÖ×Áöѧ½ç¶ÔÖйúÔÑÐÁ¢ÒìµÄ¸ß¶ÈÈϿɡ£¡£¡£¡£¡£
WCLCÊÇÌìÏÂÉϹæÄ£×î´óµÄÒԷΰ©ÎªÖ÷ÌâµÄ¶àѧ¿ÆÖ×ÁöѧÊõ¾Û»á£¬£¬£¬£¬£¬£¬£¬£¬Àú½ì¾ùÓжàÏîÖØ°õÁÙ´²Ñо¿Ð§¹ûÔÚ´ËÐû²¼²¢Ö¸µ¼ËæºóµÄÁÙ´²Êµ¼ù¸üУ¬£¬£¬£¬£¬£¬£¬£¬¿°³ÆÈ«Çò·Î°©ÁìÓòÑо¿Ï£Íû¡°·çÏò±ê¡±¡£¡£¡£¡£¡£
×÷Ϊº²ÉÖÆÒ©×ÔÖ÷Ñз¢µÄÖйúÊ׸öÔ´´Èý´úEGFR-TKI£¬£¬£¬£¬£¬£¬£¬£¬°¢ÃÀÌæÄáÒÀ¸½×¿Ô½µÄÁÆÐ§ºÍÇå¾²ÐÔÓÅÊÆ£¬£¬£¬£¬£¬£¬£¬£¬ÔøÒ»ÔÙ»ñµÃ¹ú¼ÊȨÍþÈϿɣ¬£¬£¬£¬£¬£¬£¬£¬ÔÚSCIÆÚ¿¯»ò¹ú¼Ê´ó»áÉϽÒÏþµÄÏà¹ØÐ§¹û¾ÍÒÑÁè¼Ý100ƪ¡£¡£¡£¡£¡£Îª½øÒ»²½¾ò¿Í°¢ÃÀÌæÄáÔڷΰ©Ï¸·ÖÁìÓòµÄÖÎÁÆÇ±Á¦£¬£¬£¬£¬£¬£¬£¬£¬»Ý¼°¸ü¶à·ÇСϸ°û·Î°©(NSCLC)»¼Õߣ¬£¬£¬£¬£¬£¬£¬£¬Õë¶Ô¸ü¶à˳Ӧ֢µÄÁÙ´²ÊÔÑéÕýÔÚ¼ÓËÙÍÆ½øÖУ¬£¬£¬£¬£¬£¬£¬£¬°üÀ¨°¢ÃÀÌæÄḨÖúÖÎÁÆEGFRÃô¸ÐÍ»±äNSCLC¡¢ÍŽẬ²¬Ë«Ò©»¯ÁÆÒ»ÏßÖÎÁÆEGFRÃô¸ÐÍ»±äNSCLCµÈ¶à¸öÁÙ´²Ñо¿£¬£¬£¬£¬£¬£¬£¬£¬ÒÔÆÚΪ¸ü¶àNSCLC»¼ÕßÌṩ´ÓÔçÆÚµ½ÍíÆÚ£¬£¬£¬£¬£¬£¬£¬£¬´ÓΧÊÖÊõÆÚ¸¨ÖúÖÎÁƵ½Ò»Ïß¼°ºóÏßÖÎÁƵÄÈ«·½Î»¶àά¶ÈµÄÓÃÒ©¼Æ»®¡£¡£¡£¡£¡£
±¾½ìWCLCÉÏ£¬£¬£¬£¬£¬£¬£¬£¬°¢ÃÀÌæÄá½ÒÏþµÄ42ƪЧ¹û°üÀ¨3ƪ¿ÚÍ·±¨¸æ(Ñо¿Êý¾Ý)¡¢18ƪͨÀýÕªÒª(Ñо¿Êý¾Ý)¡¢13ƪ²¡Àý±¨µÀºÍ8ƪÑо¿Éè¼Æ£¬£¬£¬£¬£¬£¬£¬£¬½«Õ¹Ê¾°¢ÃÀÌæÄáÔÚNSCLC°ÐÏòÍŽáÖÎÁÆ¡¢ÄÔ(Ĥ)×ªÒÆ¡¢Ð¸¨Öú¡¢Ï¸·ÖÈËȺ¡¢Çå¾²ÐÔ¡¢ÉúÑÄÖÊÁ¿µÈÆ«ÏòµÄ×îÐÂÑо¿Ï£Íû¡£¡£¡£¡£¡£
¿ÚÍ·±¨¸æ£º3ƪ
1.Aumolertinib Plus Anlotinib in Advanced NSCLC with Brain Metastasis: A Single-arm, Phase II Study
°¢ÃÀÌæÄáÍŽᰲÂÞÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±ä°éÄÔ×ªÒÆ»¼ÕßµÄÓÐÓÃÐÔ¼°Çå¾²ÐÔ£ºµ¥±ÛIIÆÚÑо¿
ÈëÑ¡ÐÎʽ£ºOral£¬£¬£¬£¬£¬£¬£¬£¬±àºÅ£ºOA03.03
ͨѶ×÷ÕߣºÖÐɽ´óѧÖ×Áö·ÀÖÎÖÐÐÄ£¬£¬£¬£¬£¬£¬£¬£¬³ÂÀöÀ¥
µÚÒ»×÷ÕߣºÖÐɽ´óѧÖ×Áö·ÀÖÎÖÐÐÄ£¬£¬£¬£¬£¬£¬£¬£¬³Â¾²
±¨¸æÊ±¼ä£º±±¾©Ê±¼ä2023Äê9ÔÂ10ÈÕ12:32-12:42
2.Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study
°¢ÃÀÌæÄáÍŽᰣ¿£¿£¿£¿£¿ËÌæÄáÓÃÓÚ°éÖÐÊàÉñ¾ÏµÍ³×ªÒƵÄEGFRÍ»±äNSCLCÒ»ÏßÖÎÁÆ£ºÒ»ÏîǰհÐÔ¢ñ/¢òÆÚÑо¿
ÈëÑ¡ÐÎʽ£ºMini Oral£¬£¬£¬£¬£¬£¬£¬£¬±àºÅ£ºMA13.05
ͨѶ×÷ÕߣºËÄ´¨´óѧ»ªÎ÷Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬»ÆÃľê
µÚÒ»×÷ÕߣºËÄ´¨´óѧ»ªÎ÷Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÓàÃô
±¨¸æÊ±¼ä£º±±¾©Ê±¼ä2023Äê9ÔÂ11ÈÕ15:57-16:02
3.Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial (ALWAYS)
°¢ÃÀÌæÄáÍŽᰲÂÞÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±äÐÍ·ÇСϸ°û·Î°©£ºIIÆÚÑо¿(ALWAYS)
ÈëÑ¡ÐÎʽ£ºWorkshop/Oral£¬£¬£¬£¬£¬£¬£¬£¬±àºÅ£ºWS02.12/P2.09-32
µÚÒ»×÷Õß £º¹ã¶«Ò½¿Æ´óѧÁ¥ÊôÒ½Ôº£¨Õ¿½£©£¬£¬£¬£¬£¬£¬£¬£¬³Â»ªÁÖ
±¨¸æÊ±¼ä£º±±¾©Ê±¼ä2023Äê9ÔÂ9ÈÕ10:40-10:50
Ñо¿Êý¾Ý£º18ƪ
1.Efficacy and Safety of Aumolertinib as Second- Or Third-Line Therapy in EGFR T790M Negative/Unknown Non-small Cell Lung Cancer
°¢ÃÀÌæÄá¶þÏß»òÈýÏßÖÎÁÆT790MÒõÐÔ/δ֪·ÇСϸ°û·Î°©»¼ÕßµÄÓÐÓÃÐÔºÍÇå¾²ÐÔ
ÈëÑ¡ÐÎʽ£ºPoster£¬£¬£¬£¬£¬£¬£¬£¬±àºÅ£ºP2.09-06
×÷Õߣº±±¾©Ö×ÁöÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬·½½¡
2.Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated
°¢ÃÀÌæÄá¶ÔÍíÆÚEGFRÓÐÊýÍ»±ä·ÇСϸ°û·Î°©»¼ÕßµÄÇå¾²ÐÔºÍÓÐÓÃÐÔÑо¿£ºÐÐÁÐ2Êý¾Ý¸üÐÂ
ÈëÑ¡ÐÎʽ£ºPoster, ±àºÅ£ºP2.09-07
×÷ÕߣºÖÐɽ´óѧÁ¥ÊôÖ×ÁöÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬·½ÎÄ·å
3.Increased Dose of Aumolertinib Rechallenge in Advanced NSCLC with Gradual Progression
°¢ÃÀÌæÄá¼ÓÁ¿ÔÙÌôÕ½ÖÎÁÆ»ºÂýÏ£ÍûµÄÍíÆÚ·ÇСϸ°û·Î°©»¼ÕßµÄÑо¿
ÈëÑ¡ÐÎʽ£ºPoster, ±àºÅ£ºP2.09-19
×÷Õߣº¼ªÁÖ´óѧÖÐÈÕÁªÒêÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬Àî¾ü
4.Efficacy of Aumolertinib in EGFR T790M-negative or -unknown NSCLC with Brain Metastases Following Resistance to Prior EGFR-TKIs
°¢ÃÀÌæÄáÖÎÁÆÇ°ÏßEGFR-TKIsÄÍÒ©µÄEGFRT790MÒõÐÔ»òδ֪°éÄÔ×ªÒÆµÄNSCLC»¼ÕßµÄÁÆÐ§
ÈëÑ¡ÐÎʽ£ºPoster, ±àºÅ£ºP2.09-22
×÷ÕߣºÖйúÒ½¿Æ´óѧÁ¥ÊôÊ¢¾©Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬º«¬b²¨
5.Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer: Impact on Residual GGO Lesions
°¢ÃÀÌæÄḨÖúÖÎÁƶÔÇгýµÄEGFRÍ»±äµÄ·ÇСϸ°û·Î°©ÒÔ¼°Ê£ÓàGGO²¡ÔîµÄÓ°Ïì
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP07.05-05
×÷ÕߣºËÕÖÝ´óѧÁ¥ÊôµÚÒ»Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬Âíº£ÌÎ
6.HRQoL with Adjuvant Aumolertinib in Patients with Resected Stage IB-IIIA EGFR Mutant Non-Small Cell Lung Cancer
IB-IIIAÆÚEGFRÍ»±äNSCLC»¼Õß°¢ÃÀÌæÄáÊõºó¸¨ÖúÖÎÁƵÄÉúÑÄÖÊÁ¿Ñо¿
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP07.05-14
×÷ÕߣºÎ人´óѧÖÐÄÏÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ºúÎÀ¶«
7.Aumolertinib as Neoadjuvant Therapy for EGFR-mutated Non-Small Cell Lung Cancer: A Subcohort Analysis of the PURPOSE Trial
°¢ÃÀÌæÄáи¨ÖúÖÎÁÆEGFRÍ»±äµÄ·ÇСϸ°û·Î°©£ºPURPOSEÊÔÑéµÄÑÇÐÐÁÐÆÊÎö
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP07.05-17
×÷ÕߣºÉϺ£ÊÐÐØ¿ÆÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬·½ÎÄÌÎ
8.The Safety and Efficacy of Aumolertinib in Advanced NSCLC Patients with EGFRm Who were Intolerant to Osimertinib: A Retrospective Clinical Study
°ÂÏ£ÌæÄáÇå¾²ÐÔ²»ÄÍÊÜת°¢ÃÀÌæÄáÖÎÁƵÄEGFRÑôÐÔÍ»±ä·ÇСϸ°û·Î°©»¼ÕßµÄÇå¾²ÐÔºÍÓÐÓÃÐÔ»ØÊ×ÐÔÑо¿
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-01
×÷ÕߣºÄϲý´óѧµÚÒ»Á¥ÊôÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ËïÁú»ª
9.The Safety and Efficacy of Aumolertinib in Advanced EGFR-mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment
ÍíÆÚNSCLC»¼Õß·þÓðÂÏ£ÌæÄáÄÍÊÜÐÔ²»¼Ñת»»°¢ÃÀÌæÄáµÄÇå¾²ÐÔºÍÓÐÓÃÐÔÑо¿
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-16
×÷ÕߣºáéÖÝÊÐÈËÃñÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬Ö£ÇÚºì
10.Successful Aumolertinib Treatment of Activated EGFR Mutation NSCLC Patients with Interstitial Pneumonia Induced by Osimertinib
°¢ÃÀÌæÄáÀÖ³ÉÖÎÁÆÒò°ÂÏ£ÌæÄáÒýÆð¼äÖÊÐÔ·ÎÑ×EGFRÍ»±äµÄ·ÇСϸ°û·Î°©»¼ÕßµÄÑо¿
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-19
×÷ÕߣºÕã½´óѧҽѧԺÁ¥ÊôÉÛÒÝ·òÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬³Â¶÷¹ú
11.Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results
°¢ÃÀÌæÄáÒ»ÏßÖÎÁƾֲ¿ÍíÆÚ»ò×ªÒÆÐÔEGFR¹²Í»±ä·ÇСϸ°û·Î°©£ºÒ»Ïî»ØÊ×ÐÔÑо¿
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-25
×÷ÕߣºÄϾ©ÊÐÐØ¿ÆÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬·½Éê´æ
12.Aumolertinib as Neoadjuvant and Adjuvant Therapy for Unresectable Stage IIIA-IVA Non-Small Cell Lung Cancer with EGFR Mutations
°¢ÃÀÌæÄáи¨ÖúºÍ¸¨ÖúÖÎÁÆIIIA-IVAÆÚ²»¿ÉÇгýµÄEGFRÍ»±ä·ÇСϸ°û·Î°©Ñо¿
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-26
×÷ÕߣºÄϾ©ÊÐÐØ¿ÆÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬·½Éê´æ
13.Real-World Outcomes of Health-Related Quality-of-Life (HRQoL) In Advanced Non-small Cell Lung Cancer Patients Treated with Aumolertinib
°¢ÃÀÌæÄáÖÎÁÆÍíÆÚ·ÇСϸ°û·Î°©»¼Õß¿µ½¡Ïà¹ØÉúÑÄÖÊÁ¿(HRQoL)µÄÕæÊµÌìÏÂЧ¹û
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-45
×÷ÕߣºÉ½¶«´óѧÆë³ҽԺ£¬£¬£¬£¬£¬£¬£¬£¬Àî¼ÊÊ¢
14.Study of Aumolertinib Monotherapy or Combination Treated EGFR-mutated NSCLC Patients with Symptomatic Brain Metastases
°¢ÃÀÌæÄáµ¥Ò©»òÍŽáÖÎÁÆÓÐÖ¢×´EGFRÍ»±äµÄ·ÇСϸ°û·Î°©ÄÔ×ªÒÆ»¼ÕßµÄÑо¿
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-48
×÷ÕߣººÓÄÏÊ¡Ö×ÁöÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬Íõ»Û¾ê
15.Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE)
°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±ä·ÎÏÙÁÛ°©£ºÒ»Ïî¶àÖÐÐÄ¡¢µ¥±Û¡¢Ç°Õ°ÐÔÑо¿£¨ARISE£©
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-55
×÷Õߣº¸£½¨Ê¡Ö×ÁöÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÁÖ¸ù/»ªÖпƼ¼´óѧͬ¼ÃҽѧԺÁ¥Êôͬ¼ÃÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ñÒÙ»
16.Conversion to Aumolertinib in NSCLC Patients with EGFR Mutations Who Are Safety Intolerant after Osimertinib Treatment: A Retrospective Study
°ÂÏ£ÌæÄáÖÎÁƺóÇå¾²ÐÔ²»ÄÍÊܵÄEGFRÍ»±ä·ÇСϸ°û·Î°©»¼ÕßתΪ°¢ÃÀÌæÄáµÄ»ØÊ×ÐÔÑо¿
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-63
×÷ÕߣºÍÈÊÊÐÈËÃñÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬Ò¦±ë
17.Aumolertinib Combination Therapy for EGFR-Mutant NSCLC Patients with Refractory Leptomeningeal Metastasis Following Osimertinib Failure
°¢ÃÀÌæÄáÍÅ½á¼Æ»®ÖÎÁƾ°ÂÏ£ÌæÄáÖÎÁÆÊ§°ÜµÄÄÑÖÎÐÔÄÔÄ¤×ªÒÆEGFRÍ»±ä·ÇСϸ°û·Î°©»¼Õß
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-71
×÷ÕߣºÄϾ©ÐØ¿ÆÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬·½Éê´æ
18.Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR+ NSCLC Patients: The Updated Results
°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±äµÄÍíÄê·ÇСϸ°û·Î°©»¼ÕßµÄÕæÊµÌìÏÂÑо¿
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-72
×÷ÕߣºÄϾ©ÐØ¿ÆÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬·½Éê´æ
²¡Àý±¨µÀ£º13ƪ
1.First-line Aumolertinib Treatment in Non-Small Cell Lung Cancer (NSCLC) with Primary EGFR T790M Mutation: A Report of two Cases
°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆÔ·¢ÐÔEGFR T790MÍ»±äµÄ·ÇСϸ°û·Î°©(NSCLC)£º2Àý²¡Àý±¨µÀ
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-14
×÷ÕߣºÌì½òÒ½¿Æ´óѧµÚ¶þÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ê°Á¢
2.Aumolertinib Combination SBRT Treated EGFR Co-mutation Patients with Symptomatic Brain Metastases: A Case Report
°¢ÃÀÌæÄáÍŽáSBRTÖÎÁÆEGFR¹²Í»±äÓÐÖ¢×´ÄÔ×ªÒÆ»¼Õߣº²¡Àý±¨µÀ
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-15
×÷ÕߣººÓÄÏÊ¡Ö×ÁöÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÕÅÏþ¾ê
3.A Case of Brain Metastases from Lung Cancer with Epilepsy and ECOG Score of 4 Successfully Treated with Aumolertinib
Ò»Àý°¢ÃÀÌæÄáÀÖ³ÉÖÎÁÆ·ÇСϸ°û·Î°©ÄÔ×ªÒÆ°éñ²ðïºÏ²¢PSÆÀ·Ö4·Ö»¼ÕߵIJ¡Àý±¨¸æ
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-21
×÷ÕߣºÇ廪´óѧÁ¥Êô±±¾©Ç廪³¤¸ýÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÕÔ¾°È«
4.High-Dose Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC with Meningeal Symptoms as the First Symptom
¸ß¼ÁÁ¿°¢ÃÀÌæÄáÍŽáÇÊÄÚ»¯ÁÆÖÎÁÆÒÔÄÔĤ֢״ΪÊ×·¢Ö¢×´µÄEGFRÍ»±äNSCLC»¼Õß
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-24
×÷ÕߣºÖØÇì´óѧÁ¥ÊôÈýϿҽԺ£¬£¬£¬£¬£¬£¬£¬£¬Íõΰ
5.A Case of Long PFS by Aumolertinib in Advanced Lung Cancer with Multiple Metastases lncluding Brain Metastasis
°¢ÃÀÌæÄáÖÎÁÆÍíÆÚNSCLC°éÓаüÀ¨ÄÔ×ªÒÆÔÚÄڵĶ෢ÐÔ×ªÒÆ°©»¼Õß»ñµÃÓÀÉúÑĵIJ¡Àý±¨µÀ
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-28
×÷Õߣº´óÁ¬Ò½¿Æ´óѧÁ¥ÊôµÚÒ»Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬µ¥Ðã
6.Intracranial Complete Remissions and Long-Term Response in a EGFR positive NSCLC Patient with Brain Metastases: Case Report
°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±ä°é¶à·¢ÄÔ×ªÒÆNSCLC»¼ÕßÂÄÚÍêÈ«»º½â²¢ÓÀÉúÑĵIJ¡Àý±¨µÀ
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-32
×÷Õߣº¹ãÖÝÊз¬Ø®ÖÐÐÄÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ËÕºÆÈ»
7.Exceptional Response to Aumolertinib in an Advanced NSCLC Patient With Rare EGFR Exon20 V774M and S768I Mutations
°¢ÃÀÌæÄá¶ÔÓÐÊýµÄEGFR Exon20 V774MºÍS768IÍ»±äµÄÍíÆÚ·ÇСϸ°û·Î°©»¼ÕßÓÐÓÃ
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-37
×÷Õߣº°ö²ºÒ½Ñ§ÔºµÚÒ»Á¥ÊôÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÌÕÌÎ
8.Lung Adenocarcinoma Patient with Co-mutations of MET Exon 14 Skipping and EGFR exon21 L858R responded to Aumolertinib
°¢ÃÀÌæÄáÖÎÁÆÒ»ÀýMET 14ÍâÏÔ×ÓÌøÍ»ºÏ²¢EGFR 21 L858R¹²Í»±äµÄ·ÎÏÙ°©²¡Àý±¨¸æ
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-44
×÷Õߣº¿Õ¾ü¾üÒ½´óѧÎ÷¾©Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ ³ÂÑÜ
9.Successful Salvage Therapy Using High Dose Aumolertinib in T790M-negative EGFR-mutant NSCLC With Brain and Leptomeningeal Metastases
¸ß¼ÁÁ¿°¢ÃÀÌæÄáÀÖ³ÉÕü¾È°éÄÔ¡¢ÄÔÄ¤×ªÒÆµÄT790MÒõÐÔEGFRÍ»±ä·ÇСϸ°û»¼Õß
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-56
×÷ÕߣºÏÃÃÅ´óѧÁ¥ÊôµÚÒ»Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÀîÒã±ó
10.Unresectable Advanced NSCLC Transformed to Resectable NSCLC through Effective Aumolertinib Neoadjuvant Therapy: A Case Report
²»¿ÉÇгýµÄ·ÇСϸ°û·Î°©»¼Õßͨ¹ý°¢ÃÀÌæÄáи¨ÖúÖÎÁÆ×ª»¯Îª¿ÉÇгý£º²¡Àý±¨µÀ
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-57
×÷Õߣº×ñÒåÒ½¿Æ´óѧÁ¥ÊôÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬³Â³É
11.Continuous CR for EGFR-Mutated NSCLC with Brain Metastasis and Giant Lung Lesion Using Aumolertinib Plus Radiotherapy as First-Line Treatment
°¢ÃÀÌæÄáÍŽá·ÅÁÆÒ»ÏßÖÎÁÆEGFRÍ»±äNSCLC°éÄÔ×ªÒÆºÍÖØ´ó·Î²¿²¡ÔîµÄ»¼ÕßÒ»Á¬ÐÔÍêÈ«»º½â
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-58
×÷ÕߣºËÄ´¨´óѧ»ªÎ÷Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÎâÇ¿
12.Long Survival in LM NSCLC Treated with Aumolertinib and Metronomic Intrathecal Pemetrexed under Dynamic Detection of CSF ctDNA
CSF ctDNA¶¯Ì¬¼à²âϰ¢ÃÀÌæÄáÍŽá½Ú×àʽÇÊÄÚ×¢ÉäÅàÃÀÇúÈûÖÎÁÆÄÔÄ¤×ªÒÆ·ÇСϸ°û·Î°©»¼Õß»ñµÃÓÀÉúÑÄ
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-66
×÷Õߣº´óÁ¬Ò½¿Æ´óѧÁ¥ÊôµÚ¶þÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬´÷Ôçϼ
13.Durable Response to High-Dose Aumolertinib 165mg After Local Progression in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases
°¢ÃÀÌæÄá165mg¸ß¼ÁÁ¿¶ÔEGFRÍ»±ä·ÇСϸ°û·Î°©»¼ÕßÄÔ×ªÒÆ¾Ö²¿Ï£Íûºó³¤ÆÚÓ¦´ð
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-68
×÷Õߣº°²»ÕÒ½¿Æ´óѧµÚÒ»Á¥ÊôÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬×£ÇåÇå
Ñо¿Éè¼Æ£º8ƪ
1.Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I NSCLC with High-grade Patterns and EGFR Mutations (APPOINT)
°¢ÃÀÌæÄḨÖúÖÎÁÆ¿ÉÇгýµÄIÆÚº¬¸ß¼¶±ð½á¹¹EGFRÃô¸ÐÍ»±äµÄ·ÇСϸ°û·Î°©µÄÁÆÐ§ºÍÇå¾²ÐÔÁÙ´²Ñо¿
ÈëÑ¡ÐÎʽ£ºPoster, ±àºÅ£ºP1.27-09
×÷ÕߣºÉϺ£ÊÐÐØ¿ÆÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬º«±¦»Ý¡¢·½ÎÄÌÎ/ÉϺ£ÊзοÆÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬³ÂêÆ
2.Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles
°¢ÃÀÌæÄáÍŽáÇÊÄÚ»¯ÁÆÖÎÁÆEGFRÍ»±ä·ÇСϸ°û·Î°©°éÄÔÄ¤×ªÒÆ»¼Õß¼°cfDNA¶¯Ì¬×ª±ä¶ÔÁÆÐ§ºÍÔ¤ºóµÄÕ¹Íû¼ÛÖµ
ÈëÑ¡ÐÎʽ£ºPoster, ±àºÅ£ºP2.09-16
×÷ÕߣºÖØÇì´óѧÁ¥ÊôÈýϿҽԺ£¬£¬£¬£¬£¬£¬£¬£¬Íõΰ
3.Aumolertinib Combined with Carbamazepine and Intrathecal Pemetrexed for EGFR-mutated LM NSCLC with Symptomatic Epilepsy
°¢ÃÀÌæÄáÍŽῨÂíÎ÷ƽÔÚÅàÃÀÇúÈûÇÊÄÚ×¢ÉäÖÎÁÆEGFRÍ»±äÐͷΰ©ÄÔÄ¤×ªÒÆ°©»¼ÕßÖ¢×´ÐÔñ²ðïÖеÄÁÆÐ§ÆÊÎö
ÈëÑ¡ÐÎʽ£ºPoster, ±àºÅ£ºP2.09-42
×÷Õߣº¹þ¶û±õÒ½¿Æ´óѧÁ¥ÊôµÚ¶þÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÀîÀï
4.Efficacy and safety of adjuvant aumolertinib in stage IB-IIIA NSCLC after R0 resection and the correlation between efficacy and postoperative MRD status
°¢ÃÀÌæÄáÊõºó¸¨ÖúÖÎÁÆR0ÇгýµÄIB-IIIAÆÚ·ÇСϸ°û·Î°©»¼ÕßµÄÁÆÐ§ºÍÇå¾²ÐÔ¼°ÊõºóMRDÓëÁÆÐ§Ïà¹ØÐÔµÄÑо¿
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP07.05-10
×÷Õߣº·ðɽÊеÚÒ»ÈËÃñÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÑîʤÀû
5.Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib
°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±äÑôÐÔNSCLCÄÍÒ©·Ö×Ó±ê¼ÇÎïµÄÑо¿
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-29
×÷ÕߣºÖйúҽѧ¿ÆÑ§ÔºÖ×ÁöÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬¶Î½¨´º
6.The Optimal Intervention Timing of Aumolertinib Combined with HFSRT for EGFR Mutated NSCLC Patients with Multiple Brain Metastasess
°¢ÃÀÌæÄáÍŽáHFSRTÖÎÁÆEGFRÍ»±äNSCLC¶à·¢ÄÔ×ªÒÆ»¼ÕßµÄ×î¼Ñ¸ÉԤʱ»úµÄÁÙ´²Ñо¿
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-40
×÷ÕߣºÉ½¶«Ê¡Ö×ÁöÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÉÛÙ»
7.Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy
°¢ÃÀÌæÄáÓÃÓÚÒ»/¶þ´úTKIÖÎÁƺó¸Î¹¦Ð§Òì³£»£»£»£»£»£»òδ¾ÖÎÁƺϲ¢»ù´¡ÐԸβ¡µÄEGFRÍ»±äNSCLCµÄÑо¿
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-73
×÷ÕߣºËÄ´¨´óѧ»ªÎ÷Ò½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÂÞ·æ
8.Real-world Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area
°¢ÃÀÌæÄáÖÎÁÆEGFRÓÐÊýÍ»±äÍíÆÚ·ÇСϸ°û·Î°©»¼ÕßµÄÕæÊµÌìÏÂÑо¿
ÈëÑ¡ÐÎʽ£ºE-Poster, ±àºÅ£ºEP12.01-77
×÷ÕߣºÀ¥Ã÷Ò½¿Æ´óѧµÚÒ»Á¥ÊôÒ½Ôº£¬£¬£¬£¬£¬£¬£¬£¬ÕŽ£Çà
Äú¿ÉµÇ¼ÒÔÏÂÍøÖ·£¬£¬£¬£¬£¬£¬£¬£¬Éó²é°¢ÃÀÌæÄá2023 WCLCÈëѡժҪÎÊÌâµÄÏêϸÐÅÏ¢£º
https://cattendee.abstractsonline.com/meeting/10925view=appendToCards&initialSearchId=3&searchId=3